Table 2:
Nucleic Acid-based screening assays for early detection1
| Company/PI | Test Name | Sample | Analyte/Assay | Status | Clinical Trials (NCT number) | References2 |
|---|---|---|---|---|---|---|
| Bluestar Genomics/ ClearNote Health | Avantect pancreatic cancer test | PB | 5-OH-methyl-cytosine | Development/ Live |
NCT03869814
NCT05188586 NCT05188573 |
[98,99] |
| Delfi | NA | PB | ctDNA, molecule length |
Development, anticipated 2023 |
NCT04825834
NCT05306288 |
[79,100–102] |
| EarlyDiagnostics | cfMethyl-Seq | PB | ctDNA methylation | Development | ND, Trials planned for liver and lung cancer | [103–105] |
| Exact Biosciences/ Thrive Early Detection |
CancerSEEK/ Detect-A |
PB | ctDNA and protein markers | Development |
NCT04213326
NCT04213326 |
[92] |
| Grail | Galleri | PB | ctDNA methylation | Live |
NCT05481697
NCT05611632 NCT05205967 |
[106–108] |
| Singlera Genomics | PanSeer, PDACatch | PB | ctDNA methylation |
Development |
NCT05336058
NCT05159544 NCT05431621 NCT05485077 NCT05444491 NCT05432128 NCT05536089 NCT05336539 NCT03828396 NCT05626985 NCT03685669 |
[109–113] |
1.
Assays for earlier detection of cancer are also referred to as multi-cancer early detection (MCED), in addition to liquid biopsy.
2.
As determined by an author or funding from the company, or use of the test in the study. NA: not available. ND: none detected in clinicaltrails.gov. PB= peripheral blood.